
Jonathan C Yeung

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/363342/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Normothermic Ex Vivo Lung Perfusion in Clinical Lung Transplantation. New England Journal of Medicine, 2011, 364, 1431-1440.	13.9	898
2	Technique for Prolonged Normothermic Ex Vivo Lung Perfusion. Journal of Heart and Lung Transplantation, 2008, 27, 1319-1325.	0.3	441
3	Experience with the first 50 exÂvivo lung perfusions in clinical transplantation. Journal of Thoracic and Cardiovascular Surgery, 2012, 144, 1200-1207.	0.4	270
4	Functional Repair of Human Donor Lungs by IL-10 Gene Therapy. Science Translational Medicine, 2009, 1, 4ra9.	5.8	258
5	Functional Production and Characterization of a Fibrin-Specific Single-Chain Antibody Fragment from Bacillus subtilis : Effects of Molecular Chaperones and a Wall-Bound Protease on Antibody Fragment Production. Applied and Environmental Microbiology, 2002, 68, 3261-3269.	1.4	162
6	Outcomes after transplantation of lungs preserved for more than 12 h: a retrospective study. Lancet Respiratory Medicine,the, 2017, 5, 119-124.	5.2	117
7	Extracorporeal life support as a bridge to lung transplantation–experience of a high-volume transplant center. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 1316-1328.e1.	0.4	111
8	Physiologic assessment of the ex vivo donor lung for transplantation. Journal of Heart and Lung Transplantation, 2012, 31, 1120-1126.	0.3	107
9	Long-term Outcomes of Lung Transplant With Ex Vivo Lung Perfusion. JAMA Surgery, 2019, 154, 1143.	2.2	105
10	Ex Vivo Adenoviral Vector Gene Delivery Results in Decreased Vector-associated Inflammation Pre- and Post–lung Transplantation in the Pig. Molecular Therapy, 2012, 20, 1204-1211.	3.7	101
11	Safety and Efficacy of <i>Ex Vivo</i> Donor Lung Adenoviral IL-10 Gene Therapy in a Large Animal Lung Transplant Survival Model. Human Gene Therapy, 2017, 28, 757-765.	1.4	94
12	Prevention of viral transmission during lung transplantation with hepatitis C-viraemic donors: an open-label, single-centre, pilot trial. Lancet Respiratory Medicine,the, 2020, 8, 192-201.	5.2	87
13	Development and Characterization of a Series of Soluble Tetrameric and Monomeric Streptavidin Muteins with Differential Biotin Binding Affinities. Journal of Biological Chemistry, 2001, 276, 46422-46428.	1.6	86
14	Protein Expression Profiling Predicts Graft Performance in Clinical Ex Vivo Lung Perfusion. Annals of Surgery, 2015, 261, 591-597.	2.1	83
15	Initial Experience With Lung Donation After Cardiocirculatory Death in Canada. Journal of Heart and Lung Transplantation, 2009, 28, 753-758.	0.3	77
16	Update on Donor Assessment, Resuscitation, and Acceptance Criteria, Including Novel Techniques—Non–Heart-Beating Donor Lung Retrieval and Ex Vivo Donor Lung Perfusion. Thoracic Surgery Clinics, 2009, 19, 261-274.	0.4	77
17	Overview of Clinical Lung Transplantation. Cold Spring Harbor Perspectives in Medicine, 2014, 4, a015628-a015628.	2.9	67
18	Transcriptional signatures in donor lungs from donation after cardiac death vs after brain death: A functional pathway analysis. Journal of Heart and Lung Transplantation, 2011, 30, 289-298.	0.3	59

#	Article	IF	CITATIONS
19	Novel Approaches to Expanding the Lung Donor Pool: Donation After Cardiac Death and Ex Vivo Conditioning. Clinics in Chest Medicine, 2011, 32, 233-244.	0.8	57
20	Kinetics of lactate metabolism during acellular normothermic ex vivo lung perfusion. Journal of Heart and Lung Transplantation, 2011, 30, 1312-1319.	0.3	57
21	Normothermic exÂvivo lung perfusion: Does the indication impact organ utilization and patient outcomes after transplantation?. Journal of Thoracic and Cardiovascular Surgery, 2020, 159, 346-355.e1.	0.4	44
22	Initial lung transplantation experience with uncontrolled donation after cardiac death in North America. American Journal of Transplantation, 2020, 20, 1574-1581.	2.6	42
23	The role of the endothelin-1 pathway as a biomarker for donor lung assessment in clinical ex vivo lung perfusion. Journal of Heart and Lung Transplantation, 2015, 34, 849-857.	0.3	41
24	Intraoperative extracorporeal support during lung transplantation in patients bridged with venovenous extracorporeal membrane oxygenation. Journal of Heart and Lung Transplantation, 2018, 37, 1418-1424.	0.3	41
25	Static lung storage at 10°C maintains mitochondrial health and preserves donor organ function. Science Translational Medicine, 2021, 13, eabf7601.	5.8	39
26	Efficient Gene Delivery to Pig Airway Epithelia and Submucosal Glands Using Helper-Dependent Adenoviral Vectors. Molecular Therapy - Nucleic Acids, 2013, 2, e127.	2.3	37
27	Lung transplantation for cystic fibrosis. Journal of Heart and Lung Transplantation, 2020, 39, 553-560.	0.3	36
28	Towards donor lung recovery—gene expression changes during ex vivo lung perfusion of human lungs. American Journal of Transplantation, 2018, 18, 1518-1526.	2.6	35
29	Towards personalized induction therapy for esophageal adenocarcinoma: organoids derived from endoscopic biopsy recapitulate the pre-treatment tumor. Scientific Reports, 2020, 10, 14514.	1.6	31
30	Potential therapeutic targets for lung repair during human <i>ex vivo</i> lung perfusion. European Respiratory Journal, 2020, 55, 1902222.	3.1	31
31	Ex-vivo lung perfusion. Current Opinion in Organ Transplantation, 2017, 22, 287-289.	0.8	30
32	Pig lung transplant survival model. Nature Protocols, 2018, 13, 1814-1828.	5.5	30
33	Prediction of donor related lung injury in clinical lung transplantation using a validated ex vivo lung perfusion inflammation score. Journal of Heart and Lung Transplantation, 2021, 40, 687-695.	0.3	29
34	Increased levels of interleukin- $1\hat{l}^2$ and tumor necrosis factor- $\hat{l}\pm$ in donor lungs rejected for transplantation. Journal of Heart and Lung Transplantation, 2011, 30, 452-459.	0.3	25
35	Local Long-Term Expression of Lentivirally Delivered IL-10 in the Lung Attenuates Obliteration of Intrapulmonary Allograft Airways. Human Gene Therapy, 2011, 22, 1453-1460.	1.4	24
36	How Many Nodes Need to be Removed to Make Esophagectomy an Adequate Cancer Operation, and Does the Number Change When a Patient has Chemoradiotherapy Before Surgery?. Annals of Surgical Oncology, 2020, 27, 1227-1232.	0.7	20

#	Article	IF	CITATIONS
37	Cell-free DNA in human exÂvivo lung perfusate as a potential biomarker to predict the risk of primary graft dysfunction in lung transplantation. Journal of Thoracic and Cardiovascular Surgery, 2021, 162, 490-499.e2.	0.4	20
38	Introducing the concept of semielective lung transplantation through the use of exÂvivo lung perfusion. Journal of Thoracic and Cardiovascular Surgery, 2018, 156, 2350-2352.	0.4	19
39	Transcriptomic investigation reveals donor-specific gene signatures in human lung transplants. European Respiratory Journal, 2021, 57, 2000327.	3.1	19
40	Use of metabolomics to identify strategies to improve and prolong ex vivo lung perfusion for lung transplants. Journal of Heart and Lung Transplantation, 2021, 40, 525-535.	0.3	18
41	Lung transplantation for acute COVID-19: the Toronto Lung Transplant Program experience. Cmaj, 2021, 193, E1494-E1497.	0.9	18
42	Regression of Allograft Airway Fibrosis. American Journal of Pathology, 2011, 179, 1287-1300.	1.9	17
43	Metachronous or synchronous primary lung cancer in the era of computed tomography surveillance. Journal of Thoracic and Cardiovascular Surgery, 2019, 157, 1196-1202.	0.4	16
44	Elimination of Routine Feeding Jejunostomy After Esophagectomy. Annals of Thoracic Surgery, 2020, 110, 1706-1713.	0.7	15
45	Lung donation after medical assistance in dying at home. American Journal of Transplantation, 2021, 21, 415-418.	2.6	14
46	Combined 18F-FDG PET/CT Radiomics and Sarcopenia Score in Predicting Relapse-Free Survival and Overall Survival in Patients With Esophagogastric Cancer. Clinical Nuclear Medicine, 2022, 47, 684-691.	0.7	14
47	Deceased-donor lobar lung transplant: A successful strategy for small-sized recipients. Journal of Thoracic and Cardiovascular Surgery, 2021, 161, 1674-1685.	0.4	13
48	A simplified strategy for donor-recipient size-matching in lung transplant for interstitial lung disease. Journal of Heart and Lung Transplantation, 2021, 40, 1422-1430.	0.3	13
49	Engineered mesenchymal stromal cell therapy during human lung exÂvivo lung perfusion is compromised by acidic lung microenvironment. Molecular Therapy - Methods and Clinical Development, 2021, 23, 184-197.	1.8	13
50	Prognostic significance of nutritional markers in metastatic gastric and esophageal adenocarcinoma. Cancer Medicine, 2021, 10, 199-207.	1.3	12
51	Paraconduit Hernia in the Era of Minimally Invasive Esophagectomy: Underdiagnosed?. Annals of Thoracic Surgery, 2021, 111, 1812-1819.	0.7	11
52	Design, Production, and Characterization of an Engineered Biotin Ligase (BirA) and Its Application for Affinity Purification of Staphylokinase Produced from Bacillus subtilis via Secretion. Protein Expression and Purification, 2002, 24, 357-365.	0.6	10
53	Predicting donor lung acceptance for transplant during ex vivo lung perfusion: The EX vivo lung Perfusion pREdiction (EXPIRE). American Journal of Transplantation, 2021, 21, 3704-3713.	2.6	10
54	Outcomes of lung transplantation at a Canadian center using donors declined in the United States. Journal of Thoracic and Cardiovascular Surgery, 2022, 164, 1661-1668.e1.	0.4	10

#	Article	IF	CITATIONS
55	Influence of sarcopenia, clinical data, and 2-[18F] FDG PET/CT in outcome prediction of patients with early-stage adenocarcinoma esophageal cancer. European Journal of Nuclear Medicine and Molecular Imaging, 2022, 49, 1012-1020.	3.3	9
56	miR-145 expression enhances integrin expression in SK-GT-4 cell line by down-regulating c-Myc expression. Oncotarget, 2018, 9, 15198-15207.	0.8	8
57	Using Benchmarking Standards to Evaluate Transition to Minimally Invasive Esophagectomy. Annals of Thoracic Surgery, 2020, 109, 383-388.	0.7	8
58	Impact of adjuvant therapy in patients with a microscopically positive margin after resection for gastric and esophageal cancers. Journal of Gastrointestinal Oncology, 2020, 11, 356-365.	0.6	7
59	scSNV: accurate dscRNA-seq SNV co-expression analysis using duplicate tag collapsing. Genome Biology, 2021, 22, 144.	3.8	7
60	Ex vivo lung perfusion and reconditioning. Multimedia Manual of Cardiothoracic Surgery: MMCTS / European Association for Cardio-Thoracic Surgery, 2011, 2011, mmcts.2009.004242.	0.5	6
61	Management of Complications After Esophagectomy. Thoracic Surgery Clinics, 2020, 30, 359-366.	0.4	6
62	Incidence of Ipsilateral Side Recurrence After Open or Video-Assisted Thoracic Surgery Resection of Colorectal Lung Metastases. Annals of Thoracic Surgery, 2020, 109, 1591-1597.	0.7	6
63	Outcomes of lung transplantation from organ donation after medical assistance in dying: First North American experience. American Journal of Transplantation, 2022, 22, 1637-1645.	2.6	6
64	Endobronchial ultrasound-guided bipolar radiofrequency ablation for lung cancer: A first-in-human clinical trial. Journal of Thoracic and Cardiovascular Surgery, 2022, 164, 1188-1197.e2.	0.4	5
65	Management of severe asymmetric pectus excavatum complicating aortic repair in a patient with Marfan's syndrome. Interactive Cardiovascular and Thoracic Surgery, 2016, 22, 674-675.	0.5	4
66	Bilateral Lobar Transplants Using One Donor for Two Small-Sized Recipients. Annals of Thoracic Surgery, 2020, 109, e331-e334.	0.7	4
67	Prognostic Impact of CXCR7 and CXCL12 Expression in Patients with Esophageal Adenocarcinoma. Annals of Surgical Oncology, 2021, 28, 4943-4951.	0.7	4
68	Preoperative and Postoperative Approaches to Gastroesophageal Cancer: What is All the Fuss About. Journal of the National Comprehensive Cancer Network: JNCCN, 2022, 20, 193-202.	2.3	4
69	Normothermic Ex Vivo Lung Perfusion in Clinical Lung Transplantation. Current Transplantation Reports, 2015, 2, 324-328.	0.9	2
70	Enhanced Recovery After Lung Resection Surgery: Knowing What We Can Do… and Doing It. Journal of Cardiothoracic and Vascular Anesthesia, 2020, 34, 1867-1869.	0.6	2
71	Gastric and gastroesophageal adenocarcinoma survival outcomes relative to completion of perioperative fluorouracil, leucovorin, oxaliplatin, and docetaxel (FLOT): A single-center retrospective analysis Journal of Clinical Oncology, 2021, 39, 224-224.	0.8	2
72	Importance of tumor size in resectable stage III-N2 non–small cell lung cancer. Journal of Thoracic and Cardiovascular Surgery, 2022, 164, 629-636.	0.4	2

#	Article	IF	CITATIONS
73	ExÂvivo lung evaluation of single donor lungs when theÂcontralateral lung is rejected increases safe use. Journal of Thoracic and Cardiovascular Surgery, 2023, 165, 526-531.e1.	0.4	2
74	Brain Death and Toll-Like Receptors in Lung Transplantation. Transplantation, 2010, 90, 708.	0.5	1
75	Commentary: Solitary Fibrous Tumor of the Esophagus—Rare but With Typical Characteristics. Seminars in Thoracic and Cardiovascular Surgery, 2020, 32, 179-180.	0.4	1
76	Intestinal Stem Cell Marker ASCL2 is a Novel Prognostic Predictor in Esophageal Adenocarcinoma. Cureus, 2022, 14, e21021.	0.2	1
77	Machine treatment of adult respiratory distress syndrome: Rinse or wash cycle?. Journal of Thoracic and Cardiovascular Surgery, 2018, 155, 449-450.	0.4	0
78	Transdiaphragmatic Gastroventricular Fistula. Annals of Thoracic Surgery, 2019, 107, e329-e331.	0.7	0
79	The impact of concordance with a lung cancer diagnosis pathway guideline on treatment access in patients with stage IV lung cancer. Journal of Thoracic Disease, 2020, 12, 4327-4337.	0.6	Ο
80	Esophagectomy in the setting of left sided portal hypertension. Annals of Thoracic Surgery, 2021, , .	0.7	0
81	243 PROGNOSTIC IMPACT OF CXCR7 AND CXCL12 EXPRESSION IN PATIENTS WITH ESOPHAGEAL ADENOCARCINOMA. Ecological Management and Restoration, 2021, 34, .	0.2	Ο
82	267 INTESTINAL STEM CELL MARKERS AND ITS POTENTIAL USE IN THE CLINICOPATHOLOGICAL SETTING OF ESOPHAGEAL ADENOCARCINOMA. Ecological Management and Restoration, 2021, 34, .	0.2	0
83	Commentary: Five "Ws―of pulmonary arterioplasty for lung transplantation: Who, what, why, and where. JTCVS Techniques, 2021, 9, 197-198.	0.2	Ο
84	Functional Repair of Brain Death-Injured Donor Lungs. , 2013, , 311-320.		0
85	Outcomes relative to paclitaxel dose-intensity when administered with ramucirumab in gastric and gastroesophageal junction (GEJ) adenocarcinoma Journal of Clinical Oncology, 2020, 38, e16539-e16539.	0.8	0
86	Commentary: A chance to cut is a chance to $\hat{a} \in \$ prevent metastases?. JTCVS Techniques, 2020, 3, 356-357.	0.2	0
87	Survival prediction using radiomic signatures in metastatic gastric and esophageal adenocarcinoma (GEA) Journal of Clinical Oncology, 2022, 40, 357-357.	0.8	Ο
88	Comparison of four clinical prognostic scores in patients with advanced gastric and esophageal cancer Journal of Clinical Oncology, 2022, 40, 4057-4057.	0.8	0